Treatment tolerance, tumor response, and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC) in Chinese patients
机构：[1]Chinese Acad Med Sci, Canc Inst Hosp, Beijing 100730, Peoples R China[2]Peking Union Med Coll, Beijing 100021, Peoples R China[3]Hunan Canc Hosp, Changsha, Hunan, Peoples R China[4]Cent S Univ, Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China[5]Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China[6]Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China首都医科大学宣武医院[7]Lilly Suzhou Pharmaceut Co Ltd, Shanghai Branch, Shanghai, Peoples R China[8]Eli Lilly & Co, West Ryde, Australia[9]Normin Hlth Changsha Representat Off, Changsha, Hunan, Peoples R China[10]Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
Wang Yen,Chen Jianhua,Wu Shengqi,et al.Treatment tolerance, tumor response, and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC) in Chinese patients[J].JOURNAL OF CLINICAL ONCOLOGY.2014,32(15):doi:10.1200/jco.2014.32.15_suppl.e19138.
APA：
Wang, Yen,Chen, Jianhua,Wu, Shengqi,Hu, Chengping,Li, Xiaoling...&Chen, Wendong.(2014).Treatment tolerance, tumor response, and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC) in Chinese patients.JOURNAL OF CLINICAL ONCOLOGY,32,(15)
MLA：
Wang, Yen,et al."Treatment tolerance, tumor response, and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC) in Chinese patients".JOURNAL OF CLINICAL ONCOLOGY 32..15(2014)
医学